Thomas C. Daubert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thomas C. Daubert has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Goffi
Department of Medicine and Interdepartmental Division of Critical Care Medicine, University of Toronto, Ontario, Canada
1 shared publication Andrea Daly
Department of Medicine, Division of Cardiology, Trillium Health Partners, Ontario, Canada
1 shared publicationAndrew Patterson
Department of Anesthesia, Division of Critical Care Medicine, Emory University, Atlanta, GA, USA
1 shared publication- Anil K. Gehi
University of North Carolina at Chapel Hill
1 shared publication - Anthony J. Mazzella
University of North Carolina at Chapel Hill
1 shared publication - Babar Fiza
Department of Anesthesia, Division of Critical Care Medicine, Emory University, Atlanta, GA, USA
1 shared publication
Latest Publications
- Open Access
- 17 February 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (4) , e044151
Assessing Potential Benefit of Stroke Prophylaxis Therapy in Atrial Fibrillation and Atrial Flutter Using a Novel Competing Risk Scoring Tool
Background: The competing risk of nonstroke mortality may limit the potential benefit of stroke prophylaxis therapy in patients with atrial fibrillation or atrial flutter AF. Methods: Using a Medicare 20% sample, we identified a cohort of beneficiaries diagnosed with atrial fibrillation or atrial flutter from 2006 to 2019 using International Classification of Diseases, Ninth Revision ( ICD‐9 ) and Tenth Revision ( ICD‐10 ) codes. Fine and Gray regression analysis determined the hazard of stroke with a competing risk of nonstroke mortality, and Cox proportional hazard analysis determined risk of nonstroke mortality. A scoring tool stratified patients into low or high potential benefit for thromboembolic prophylaxis. Results: Among a total of 1 883 759 Medicare beneficiaries, 330 136 patients were included with median age of 79.7 years. 54% of patients had prior bleeding episodes. The median CHA 2 DS 2 ‐VASc score was 5. Of these patients, 211 791 (64%) died and 77 717 (24%) experienced an embolic stroke over median follow‐up of 7.3 years. In the high potential benefit group (26.1%), the risk of stroke was much higher than the risk of nonstroke mortality at 1 year (12.2% versus 7.1%); 3 years (22.7% versus 16.9%); 5 years (31.9% versus 26.1%). In the low potential benefit group (73.9%), the risk of stroke was much lower than the risk of nonstroke mortality at 1 year (11.5% versus 39.2%); 3 years (23.2 versus 57.2%); and 5 years (34.3% versus 69.4%). Conclusions: We propose a scoring tool to identify the potential benefit of thromboembolic prophylaxis therapy in older patients diagnosed with atrial fibrillation or atrial flutter. This tool can be used in shared decision‐making settings. Further studies to improve and validate this scoring tool are warranted.
- 17 February 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (4) , e044151
Open AccessAssessing Potential Benefit of Stroke Prophylaxis Therapy in Atrial Fibrillation and Atrial Flutter Using a Novel Competing Risk Scoring Tool
Background: The competing risk of nonstroke mortality may limit the potential benefit of stroke prophylaxis therapy in patients with atrial fibrillation or atrial flutter AF. Methods: Using a Medicare 20% sample, we identified a cohort of beneficiaries diagnosed with atrial fibrillation or atrial flutter from 2006 to 2019 using International Classification of Diseases, Ninth Revision ( ICD‐9 ) and Tenth Revision ( ICD‐10 ) codes. Fine and Gray regression analysis determined the hazard of stroke with a competing risk of nonstroke mortality, and Cox proportional hazard analysis determined risk of nonstroke mortality. A scoring tool stratified patients into low or high potential benefit for thromboembolic prophylaxis. Results: Among a total of 1 883 759 Medicare beneficiaries, 330 136 patients were included with median age of 79.7 years. 54% of patients had prior bleeding episodes. The median CHA 2 DS 2 ‐VASc score was 5. Of these patients, 211 791 (64%) died and 77 717 (24%) experienced an embolic stroke over median follow‐up of 7.3 years. In the high potential benefit group (26.1%), the risk of stroke was much higher than the risk of nonstroke mortality at 1 year (12.2% versus 7.1%); 3 years (22.7% versus 16.9%); 5 years (31.9% versus 26.1%). In the low potential benefit group (73.9%), the risk of stroke was much lower than the risk of nonstroke mortality at 1 year (11.5% versus 39.2%); 3 years (23.2 versus 57.2%); and 5 years (34.3% versus 69.4%). Conclusions: We propose a scoring tool to identify the potential benefit of thromboembolic prophylaxis therapy in older patients diagnosed with atrial fibrillation or atrial flutter. This tool can be used in shared decision‐making settings. Further studies to improve and validate this scoring tool are warranted.
- Open Access
Cardiovascular complications are rare in severe COVID-19 presenting with myocardial injury
Background: SARS-COV2 infection has been linked to cardiovascular complications. Previously published data suggested that cardiac injury may be a common disease feature and contribute to morbidity and mortality in severe COVID-19. Since the early days of the pandemic, little data has emerged describing what cardiovascular complications arise from myocardial injury in severe COVID-19 and whether these complications contribute to mortality. Objectives: Describe the incidence and nature of cardiovascular complications in patients with severe COVID-19 infection and biochemical or imaging evidence of myocardial injury. Methods: We analyzed consecutive patients admitted for severe COVID-19 and presenting with biochemical or echocardiographic evidence of myocardial injury across 16 centers within the CARDIO-COVID investigator-initiated consortium. A light-GBM machine learning model was used to identify variables associated with mortality. Results: Our study included 1,328 patients. In hospital mortality was 29.4%. Factors most associated with mortality were age, SOFA Cardiovascular score, elevated troponin, intubation, high vasoactive-inotropic score (VIS), high PEEP, and high FiO2. Cardiovascular complications were rare and did not present significant association with mortality. Patients with high VIS and SOFA Cardiovascular scores had a significantly higher incidence of secondary bacterial pneumonias suggesting septic shock played a role in their physiology. Investigator-adjudicated cause of death data identified respiratory failure and septic shock as primary causes of mortality. Conclusions: Cardiovascular complications of severe COVID-19 are uncommon and do not seem to contribute significantly to mortality. Biochemical markers of myocardial injury or strain still carry significant prognostic value, but the value of these markers may indicate presence of high-risk ARDS phenotypes as opposed to significant myocardial injury.
Open AccessCardiovascular complications are rare in severe COVID-19 presenting with myocardial injury
Background: SARS-COV2 infection has been linked to cardiovascular complications. Previously published data suggested that cardiac injury may be a common disease feature and contribute to morbidity and mortality in severe COVID-19. Since the early days of the pandemic, little data has emerged describing what cardiovascular complications arise from myocardial injury in severe COVID-19 and whether these complications contribute to mortality. Objectives: Describe the incidence and nature of cardiovascular complications in patients with severe COVID-19 infection and biochemical or imaging evidence of myocardial injury. Methods: We analyzed consecutive patients admitted for severe COVID-19 and presenting with biochemical or echocardiographic evidence of myocardial injury across 16 centers within the CARDIO-COVID investigator-initiated consortium. A light-GBM machine learning model was used to identify variables associated with mortality. Results: Our study included 1,328 patients. In hospital mortality was 29.4%. Factors most associated with mortality were age, SOFA Cardiovascular score, elevated troponin, intubation, high vasoactive-inotropic score (VIS), high PEEP, and high FiO2. Cardiovascular complications were rare and did not present significant association with mortality. Patients with high VIS and SOFA Cardiovascular scores had a significantly higher incidence of secondary bacterial pneumonias suggesting septic shock played a role in their physiology. Investigator-adjudicated cause of death data identified respiratory failure and septic shock as primary causes of mortality. Conclusions: Cardiovascular complications of severe COVID-19 are uncommon and do not seem to contribute significantly to mortality. Biochemical markers of myocardial injury or strain still carry significant prognostic value, but the value of these markers may indicate presence of high-risk ARDS phenotypes as opposed to significant myocardial injury.